J

Johnson & Johnson

Makes prescription drugs and medical devices

Medical Science Liaison - Neuroscience

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Master's, PharmD, PhD, MD
Seoul, South Korea
In PersonDomestic and international travel is required.
Biology & Biotech

About the job

Requirements
  • A relevant science background, such as medicine, pharmacy, or life science.
  • Understanding of local regulatory policy and industry codes of practice related to drug registration, pharmaceutical promotion, and clinical studies.
  • Knowledge of scientific and therapeutic principles, with strengths in research and interpretation of scientific publications.
  • Expertise in research methodologies, clinical trial design, and related processes.
  • Excellent spoken and written English language skills.
  • Interpersonal and communication skills to interact effectively with a broad range of external and internal personnel.
  • Familiarity with Microsoft Word, Excel, and PowerPoint.
  • Awareness of and adherence to Johnson & Johnson Credo values and the International Health Care Business Integrity Guide.
  • Ability to travel domestically and internationally.
Responsibilities
  • Build scientific relationships with medical key opinion leaders and understand unmet medical needs in the assigned therapeutic area, serving as a field-based medical communication channel for Medical Affairs.
  • Contribute to developing and maintaining a medical strategy plan aligned with the cross-functional therapeutic area and company strategy through collaboration with internal and external stakeholders.
  • Conduct all activities in accordance with current regulatory and healthcare compliance guidelines.
  • Develop and maintain external relationships with key individuals to identify scientific needs and stay abreast of current scientific trends.
  • Conduct balanced communication with key individuals to understand their perspectives through individual or group discussions, presentations, and remote communications.
  • Provide clinical support to key individuals and physicians on the clinical application of established and pipeline products.
  • Respond to unsolicited requests for scientific information and, as needed, discuss disease-state concepts and in-depth medical topics while ensuring medical accuracy and compliance with local procedures, ethical guidelines, and legal directives.
  • Develop individual plans and objectives aligned with Medical Affairs strategy and approved by the manager, including a core list of key individuals for regular interactions, and use iMedical CRM to track and evaluate progress against the plan.
  • Integrate scientific data into real-life practice to meet customer needs and adapt interpersonal styles to different situations and individuals.
  • Anticipate the responses of different individuals and teams based on their perspectives.
  • Generate and share meaningful medical insights during interactions with key individuals.
  • Execute plans for proactive and reactive outreach as approved through the legal/HCC exceptions process.
  • Identify educational gaps and opportunities using a strategic approach.
  • Represent and support scientific meetings, including congresses, symposia, advisory boards, and investigator meetings.
  • Interpret findings and report them with recommendations for action to relevant internal partners.
  • Leverage knowledge of standards of care, company-sponsored clinical trials, investigator-initiated studies, and the competitive landscape to facilitate external-internal research communication.
  • Address and manage investigator-initiated studies upon external requests.
  • Engage with external investigators regarding unsolicited research inquiries and act as liaison to the Clinical Research team, including GCO and PADU.
  • Provide clinical trial support to identify potential sites, resolve issues with enrolled sites, and participate in meetings as appropriate, including site initiation visits and investigator meetings upon request.
  • Collect and provide meaningful medical insights to medical and cross-functional organizations to support strategy development.
  • Support initial and ongoing medical/scientific area and product-specific training and provide key scientific updates to internal stakeholders, as necessary and appropriate.
Desired Qualifications
  • An advanced degree of Master of Science or higher, such as a PhD, MD, or PharmD.
  • Experience in the pharmaceutical or related industries.
  • Analytical reasoning.
  • Analytics dashboards.
  • Clinical experience.
  • Coaching.
  • Competitive landscape analysis.
  • Cross-functional collaboration.
  • Data gathering and analysis.
  • Digital culture.
  • Digital literacy.
  • Interpersonal influence.
  • Market research.
  • Medical Affairs.
  • Medical communications.
  • Medical compliance.
  • Problem solving.
  • Scientific research.
  • Stakeholder engagement.
  • Strategic thinking.
  • Technical credibility.
  • Technological proficiency.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.